223 related articles for article (PubMed ID: 38611096)
1. Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic Reprogramming beyond the Warburg Effect.
Afonso J; Barbosa-Matos C; Silvestre R; Pereira-Vieira J; Gonçalves SM; Mendes-Alves C; Parpot P; Pinto J; Carapito Â; Guedes de Pinho P; Santos L; Longatto-Filho A; Baltazar F
Cancers (Basel); 2024 Apr; 16(7):. PubMed ID: 38611096
[TBL] [Abstract][Full Text] [Related]
2. Blocking integrin β1 decreases adhesion in chemoresistant urothelial cancer cell lines.
Vallo S; Rutz J; Kautsch M; Winkelmann R; Michaelis M; Wezel F; Bartsch G; Haferkamp A; Rothweiler F; Blaheta RA; Cinatl J
Oncol Lett; 2017 Nov; 14(5):5513-5518. PubMed ID: 29113179
[TBL] [Abstract][Full Text] [Related]
3. Glucose Metabolism Reprogramming in Bladder Cancer: Hexokinase 2 (HK2) as Prognostic Biomarker and Target for Bladder Cancer Therapy.
Afonso J; Gonçalves C; Costa M; Ferreira D; Santos L; Longatto-Filho A; Baltazar F
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765947
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin resistance by induction of aldo-keto reductase family 1 member C2 in human bladder cancer cells.
Shirato A; Kikugawa T; Miura N; Tanji N; Takemori N; Higashiyama S; Yokoyama M
Oncol Lett; 2014 Mar; 7(3):674-678. PubMed ID: 24527071
[TBL] [Abstract][Full Text] [Related]
5. Discovery and Validation of Nitroxoline as a Novel STAT3 Inhibitor in Drug-resistant Urothelial Bladder Cancer.
Lin W; Sun J; Sadahira T; Xu N; Wada K; Liu C; Araki M; Xu A; Watanabe M; Nasu Y; Huang P
Int J Biol Sci; 2021; 17(12):3255-3267. PubMed ID: 34421363
[TBL] [Abstract][Full Text] [Related]
6. LncRNA XIST Contributes to Cisplatin Resistance of Lung Cancer Cells by Promoting Cellular Glycolysis through Sponging miR-101-3p.
Hua G; Zeng ZL; Shi YT; Chen W; He LF; Zhao GF
Pharmacology; 2021; 106(9-10):498-508. PubMed ID: 34352791
[TBL] [Abstract][Full Text] [Related]
7. Effects of Lactate Transport Inhibition by AZD3965 in Muscle-Invasive Urothelial Bladder Cancer.
Silva A; Félix A; Cerqueira M; Gonçalves CS; Sampaio-Marques B; Longatto-Filho A; Baltazar F; Afonso J
Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38140029
[TBL] [Abstract][Full Text] [Related]
8. Revisiting the Warburg effect: historical dogma versus current understanding.
Vaupel P; Multhoff G
J Physiol; 2021 Mar; 599(6):1745-1757. PubMed ID: 33347611
[TBL] [Abstract][Full Text] [Related]
9. Loss of PTEN expression is associated with PI3K pathway-dependent metabolic reprogramming in hepatocellular carcinoma.
Zhao C; Wang B; Liu E; Zhang Z
Cell Commun Signal; 2020 Aug; 18(1):131. PubMed ID: 32831114
[TBL] [Abstract][Full Text] [Related]
10. Adseverin: a novel cisplatin-resistant marker in the human bladder cancer cell line HT1376 identified by quantitative proteomic analysis.
Miura N; Takemori N; Kikugawa T; Tanji N; Higashiyama S; Yokoyama M
Mol Oncol; 2012 Jun; 6(3):311-22. PubMed ID: 22265592
[TBL] [Abstract][Full Text] [Related]
11. miR34a/GOLPH3 Axis abrogates Urothelial Bladder Cancer Chemoresistance via Reduced Cancer Stemness.
Zhang Q; Zhuang J; Deng Y; Yang L; Cao W; Chen W; Lin T; Lv X; Yu H; Xue Y; Guo H
Theranostics; 2017; 7(19):4777-4790. PubMed ID: 29187903
[No Abstract] [Full Text] [Related]
12. The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance.
Woolbright BL; Choudhary D; Mikhalyuk A; Trammel C; Shanmugam S; Abbott E; Pilbeam CC; Taylor JA
Mol Cancer Ther; 2018 Sep; 17(9):2004-2012. PubMed ID: 29907593
[TBL] [Abstract][Full Text] [Related]
13. Glycolytic reprogramming in macrophages and MSCs during inflammation.
Li X; Shen H; Zhang M; Teissier V; Huang EE; Gao Q; Tsubosaka M; Toya M; Kushioka J; Maduka CV; Contag CH; Chow SK; Zhang N; Goodman SB
Front Immunol; 2023; 14():1199751. PubMed ID: 37675119
[TBL] [Abstract][Full Text] [Related]
14. Induction of drug-resistant bladder carcinoma cells in vitro: impact on polychemotherapy with cisplatin, methotrexate and vinblastine (CMV).
Rohde D; Brehmer B; Kapp T; Valdor M; Jakse G
Urol Res; 1998; 26(4):249-57. PubMed ID: 9759998
[TBL] [Abstract][Full Text] [Related]
15. Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer.
Wangpaichitr M; Wu C; Li YY; Nguyen DJM; Kandemir H; Shah S; Chen S; Feun LG; Prince JS; Kuo MT; Savaraj N
Oncotarget; 2017 Jul; 8(30):49275-49292. PubMed ID: 28525376
[TBL] [Abstract][Full Text] [Related]
16. Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells.
Ippolito L; Marini A; Cavallini L; Morandi A; Pietrovito L; Pintus G; Giannoni E; Schrader T; Puhr M; Chiarugi P; Taddei ML
Oncotarget; 2016 Sep; 7(38):61890-61904. PubMed ID: 27542265
[TBL] [Abstract][Full Text] [Related]
17. Quantifying intracellular rates of glycolytic and oxidative ATP production and consumption using extracellular flux measurements.
Mookerjee SA; Gerencser AA; Nicholls DG; Brand MD
J Biol Chem; 2017 Apr; 292(17):7189-7207. PubMed ID: 28270511
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition.
Cruz-Bermúdez A; Laza-Briviesca R; Vicente-Blanco RJ; García-Grande A; Coronado MJ; Laine-Menéndez S; Palacios-Zambrano S; Moreno-Villa MR; Ruiz-Valdepeñas AM; Lendinez C; Romero A; Franco F; Calvo V; Alfaro C; Acosta PM; Salas C; Garcia JM; Provencio M
Free Radic Biol Med; 2019 May; 135():167-181. PubMed ID: 30880247
[TBL] [Abstract][Full Text] [Related]
19. Matrine combined with cisplatin synergistically inhibited urothelial bladder cancer cells via down-regulating VEGF/PI3K/Akt signaling pathway.
Liao XZ; Tao LT; Liu JH; Gu YY; Xie J; Chen Y; Lin MG; Liu TL; Wang DM; Guo HY; Mo SL
Cancer Cell Int; 2017; 17():124. PubMed ID: 29299027
[TBL] [Abstract][Full Text] [Related]
20. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression.
Vaupel P; Schmidberger H; Mayer A
Int J Radiat Biol; 2019 Jul; 95(7):912-919. PubMed ID: 30822194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
